Hoth Therapeutics, Inc. (HOTH)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
HOTH Insider Trading Activity
HOTH Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $16,750 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Knie Robb | CEO and President | 1 | $16,750 | 0 | $0 | $16,750 |
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Insider Activity of Hoth Therapeutics, Inc.
Over the last 12 months, insiders at Hoth Therapeutics, Inc. have bought $16,750 and sold $0 worth of Hoth Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Hoth Therapeutics, Inc. have bought $16,750 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Knie Robb (CEO and President) — $16,750.
The last purchase of 25,000 shares for transaction amount of $16,750 was made by Knie Robb (CEO and President) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Hoth Therapeutics, Inc.
| 2024-08-16 | Knie Robb | CEO and President | 25,000 0.5041% | $0.67 | $16,750 | +27.41% | ||
| 2020-05-26 | Sale | Hayes Anthony | 0 – | $0 | $0 | -25.09% |
HOTH Institutional Investors: Active Positions
| Increased Positions | 7 | +41.18% | 57,829 | +15.78% |
| Decreased Positions | 7 | -41.18% | 180,411 | -49.23% |
| New Positions | 4 | New | 31,214 | New |
| Sold Out Positions | 3 | Sold Out | 154,584 | Sold Out |
| Total Postitions | 17 | company.total | 243,916 | -33.45% |
HOTH Ownership Change vs Market
Institutional Investor Ownership
| Geode Capital Management, Llc | $104.00 | 0.74% | 95,946 | +13,038 | +15.73% | 2024-12-31 |
| Vanguard Group Inc | $42.00 | 0.3% | 38,804 | 0 | 0% | 2024-12-31 |
| Two Sigma Securities, Llc | $35.00 | 0.25% | 32,206 | +13,576 | +72.87% | 2024-12-31 |
| Ubs Group Ag | $33.00 | 0.24% | 30,993 | -25,471 | -45.11% | 2024-12-31 |
| Foundations Investment Advisors, Llc | $16.00 | 0.12% | 15,000 | +15,000 | New | 2024-12-31 |
| Two Sigma Investments, Lp | $12.00 | 0.09% | 11,100 | +11,100 | New | 2024-12-31 |
| Morgan Stanley | $11.00 | 0.08% | 10,006 | -314 | -3.04% | 2024-12-31 |
| Citigroup Inc | $5.00 | 0.04% | 4,553 | +4,553 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $5.00 | 0.03% | 4,440 | -41 | -0.92% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $1.00 | <0.01% | 561 | +561 | New | 2024-12-31 |